enalapril + atorvastatin

This combination therapy refers to the background regimen of the ACE inhibitor enalapril and the statin atorvastatin, which was evaluated in a pilot randomized controlled trial led by Dr. Josep M. Cruzado for patients with poor-prognosis IgA nephropathy. In the study, this regimen served as the standard-of-care control arm against which the addition of low-dose sirolimus was tested. Enalapril functions by inhibiting the angiotensin-converting enzyme, thereby reducing systemic and glomerular blood pressure and proteinuria, which are critical factors in slowing the progression of chronic kidney disease. Atorvastatin, an HMG-CoA reductase inhibitor, is primarily used to manage dyslipidemia but may also offer pleiotropic anti-inflammatory and anti-fibrotic benefits in the renal microenvironment. The trial demonstrated that while this combination is a foundational treatment, the addition of sirolimus further stabilized renal function and reduced glomerular proliferative lesions.

Other names

ace inhibitor + statinenalapril and atorvastatin